Effect of cA2 Anti–Tumor Necrosis Factor-α Antibody Therapy on Hematopoiesis of Patients with Myelodysplastic Syndromes

Anna Boula(University of Crete), Helen Α. Papadaki(University of Crete), Fotini Markidou(University of Crete), Charalampos Pontikoglou(University of Crete), Stavroula Giannouli(National and Kapodistrian University of Athens), George Katrinakis(University of Crete), Maria Psyllaki(University of Crete), George D. Eliopoulos(University of Crete), Michael Voulgarelis(National and Kapodistrian University of Athens)
Clinical Cancer Research
May 15, 2006
10.1158/1078-0432.ccr-06-0254
Cited by 27

Related Papers

Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2
|Nature Genetics|2003|389
Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti–tumor necrosis factor-α antibody therapy
|Blood|2002|266
Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|154
Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha–mediated effect
|Blood|2002|138
Multicentric Castleman's disease
|AIDS|2004|121